Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced ...
In this abstract, Halda will present clinical and safety data from its first-in-human, multicenter, open label Phase 1/2 study ( NCT06800313) to evaluate monotherapy safety, tolerability, and clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback